Kane Biotech Makes First Commercial Sale of revyve™ Antimicrobial Wound Gel to ProgenaCare Global
Kane Biotech has achieved a major milestone by making its first commercial sale of revyve™ Antimicrobial Wound Gel to ProgenaCare Global. This follows the fulfillment of a USD$500,000 initial manufacturing scale-up fee from an exclusive US distribution agreement signed in May 2023. The product had received FDA 510(k) clearance, and Kane has collaborated with Halo Pharma for technology transfer and manufacturing scale-up phases. The company also signed a four-year manufacturing services agreement with Halo Pharma. ProgenaCare’s CEO reported excellent feedback from the initial launch, and both companies are optimistic about meeting growing demand with full-scale production.
- First commercial sale of revyve™ Antimicrobial Wound Gel to ProgenaCare Global.
- Fulfillment of USD$500,000 initial manufacturing scale-up fee.
- FDA 510(k) clearance for revyve™ Antimicrobial Wound Gel.
- Signed a four-year manufacturing services agreement with Halo Pharma.
- Positive feedback from initial launch.
- None.
Kane Also Signs Long-Term Manufacturing Agreement With Halo Pharma
WINNIPEG, Manitoba, June 27, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it has made its first commercial-scale sale of revyve™ Antimicrobial Wound Gel product (“revyve™”) to ProgenaCare Global LLC (“ProgenaCare”).
Kane has now completely fulfilled its obligation related to the USD
“This is another major milestone for Kane,” said Marc Edwards, President & CEO. “There has been a significant buildup of interest and demand for revyve™ amongst ProgenaCare’s customers as well as Kane’s existing and potential distributor network globally.”
“We are delighted to have revyve™ in full scale commercial production,” said Howard Walthall, CEO, ProgenaCare Global. “The feedback from patients and clinicians on the product from our limited initial launch has been excellent. With ample quantities now available, we look forward to being able to help even more patients along their healing journey.”
Kane recently presented new in vitro data on the efficacy of revyve™ Antimicrobial Wound Gel at the Symposium on Advanced Wound Care (SAWC), Special Operations Medical Association (SOMA), and Medical Technology Enterprise Consortium (MTEC) conferences.
Kane also announces that it has signed a four-year commercial manufacturing services agreement with Halo Pharma for the manufacturing of revyve™. Manufacturing will take place at Halo Pharma’s cGMP compliant pharmaceutical manufacturing and packaging facility located in Mirabel, Quebec. “We worked closely with Halo over the last year during the technology transfer and scale-up phases,” said Mr. Edwards. “We will be placing orders for revyve™ at full-scale manufacturing volumes as we look forward to meeting market demand for this product.”
About Kane Biotech
Kane Biotech Inc. is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. Kane has a portfolio of biotechnologies, intellectual property (67 patents and patents pending, trade secrets and trademarks) and products developed by Kane's own biofilm research expertise and acquired from leading research institutions. DispersinB®, coactiv+™, coactiv+®, DermaKB™, DermaKB Biofilm™, and revyve™ are trademarks of Kane Biotech Inc. Kane is listed on the TSX Venture Exchange under the symbol "KNE" and on the OTCQB Venture Market under the symbol “KNBIF”.
About ProgenaCare
ProgenaCare is a purpose-driven medical device company leveraging cutting-edge advances in biomaterials and medical device technologies to provide effective, affordable advanced wound care solutions to patients across the socioeconomic spectrum and around the world.
About Halo Pharma
Halo Pharma is a leading provider of pharmaceutical services, including contract dosage form development, commercial manufacturing, and analytical services. Halo Pharma’s capabilities in the areas of tech transfer, process and pharmaceutical product development, formulation development, production, scale-up and validation, and analytical method development allow it to partner with clients from development through commercialization or at any point along the way.
For more information:
| Marc Edwards | Ray Dupuis | ||||
| Chief Executive Officer | Chief Financial Officer | ||||
| Kane Biotech Inc | Kane Biotech Inc | ||||
| medwards@kanebiotech.com | rdupuis@kanebiotech.com | ||||
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Information
This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to Kane’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of Kane to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by Kane with applicable securities regulatory authorities, available at www.sedarplus.ca. Kane cautions that the foregoing list of factors that may affect future results is not exhaustive.
FAQ
What product did Kane Biotech first sell commercially to ProgenaCare Global?
What was the initial manufacturing scale-up fee associated with Kane Biotech's revyve™ Antimicrobial Wound Gel?
When did Kane Biotech sign the exclusive US distribution agreement for the revyve™ Antimicrobial Wound Gel?
What regulatory clearance did revyve™ Antimicrobial Wound Gel receive?
Which company did Kane Biotech sign a long-term manufacturing agreement with?
Where will the manufacturing of revyve™ take place?
What feedback did ProgenaCare Global report regarding the initial launch of revyve™?
